TITLE

UCB UNVEILS CIMPLICITY FOR CIMZIA TREATMENT SUPPORT

PUB. DATE
June 2008
SOURCE
Worldwide Biotech;Jun2008, Vol. 20 Issue 6, p2
SOURCE TYPE
Trade Publication
DOC. TYPE
Product Review
ABSTRACT
The article announces the launch of the CIMplicity program of UCB to enhance treatment support for patients with Crohn's disease.
ACCESSION #
32474191

 

Related Articles

  • UCB makes R&D investment.  // Chemical Week;8/7/1996, Vol. 158 Issue 30, p6 

    Reports on UCB's investment in a research and administrative center in Brussels, Belgium.

  • ABOUT UCB.  // Worldwide Biotech;Aug2011, Vol. 23 Issue 8, p6 

    The article provides information on UCB, a biopharmaceutical firm based in Brussels, Belgium, with over 8,000 employees in 40 countries, and is listed on the Euronext Brussels under the UCB symbol.

  • UCB-Bioproducts.  // BioPharm International;Dec2001, Vol. 14 Issue 12, p86 

    Focuses on the corporate capabilities of UCB-Bioproducts in Georgia. Company profile; Services offered; Marketing strategies.

  • UCB plans jv resins plant in Shanghai.  // Chemical Market Reporter;11/16/98, Vol. 254 Issue 20, p28 

    Reports on UCB SA's plan to construct a chemical plant in Shanghai, China to manufacture Cryloat polyester resins for solvent-free powder paints.

  • Pharma: Other News To Note.  // BioWorld Today;4/3/2013, Vol. 24 Issue 63, p9 

    The article reports that Health Canada approved Neupro (rotigotine) non-ergolinic dopamine agonist in patch form, from UCB SA.

  • VIMPAT.  // Physician Assistants' Prescribing Reference;Fall2009, Vol. 16 Issue 3, pA12 

    The article evaluates the Vimpat (Lacosamide) antiepileptic drugs from UCB Sa.

  • VIMPAT.  // MPR - Residents' Edition;Fall/Winter2009, Vol. 18 Issue 2, pA6 

    The article evaluates the antiepileptic drug Vimpat from UCB SA.

  • UCB Posts an Earnings Gain.  // Chemical Week;3/26/2003, Vol. 165 Issue 12, p6 

    Reports on the earning increase posted by UCB in 2002. Details of the group pretax operating profit of the firm; Sales performance of the chemical company.

  • UCB: Strong Future for Peptide-Based Therapies. Scott, Alex // Chemical Week;12/11/2002, Vol. 164 Issue 48, p27 

    Presents information on the prediction of Braine-l' Alleud, Belgium-based UCB-Bioproducts regarding the sales growth of peptide-based active pharmaceutical ingredients. Applications of peptide-based therapies; Reason behind the growth of peptide-based therapies.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics